Oncoscience | August 22nd, 2017
We are now Oncoscience GmbH. Managing directors are Dr. Dirk Reuter, Dr. Budhi Simon and Robert Ellerson....
Oncoscience AG attends the Nimotuzumab Global Scientific Meeting, 7th-10th April 2016 in Varadero/ Cuba
Oncoscience | April 7th, 2016
At this global clinical development meeting, more than 150 researches from over 20 countries discuss the latest results ...
Oncoscience | July 22nd, 2015
The acquisition enables Innokeys to fully lead clinical and commercial development of Nimotuzumab in Europe. Transactio...
Oncoscience | July 7th, 2010
Oncoscience, Wedel and GenIlac, Ankara agree on cooperation in Turkey for Nimotuzumab(Theraloc®), an EGFr antibody, whi...
Oncoscience AG presents results from Phase III study of Nimotuzumab (Theraloc®) in patients with diffuse intrinsic pontine glioma at the 41. SIOP, Sao Paulo, Brazil, October 6th-9th, 2009
Oncoscience | October 9th, 2009
On Friday October 9th, 2009 results from the Phase III study of the monoclonal antibody Nimotuzumab were presented. At ...